Rehmann Capital Advisory Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Rehmann Capital Advisory Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$10.3K	Hold	379	–	–	﹤0.01%	1040
2019 Q2	$9.12K	Sell	379 -435	-53%	-$11K	﹤0.01%	1378
2019 Q1	$21.5K	Buy	814 +435	+115%	+$10.3K	﹤0.01%	1096
2018 Q4	$7.41K	Hold	379	–	–	﹤0.01%	1151
2018 Q3	$7.42K	Buy	379 +51	+16%	+$970	﹤0.01%	1450
2018 Q2	$5.43K	Hold	328	–	–	﹤0.01%	1523
2018 Q1	$5K	Buy	+328	New	+$4.85K	﹤0.01%	1543

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Rehmann Capital Advisory Group's HZNP Position: Q3 2019 in Review

Rehmann Capital Advisory Group held its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) position steady in Q3 2019 at 379 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1040.

Rehmann Capital Advisory Group first reported a position in HZNP in Q1 2018 and has held it in 7 quarters since. The position peaked at $21.5K in Q1 2019. 264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

Rehmann Capital Advisory Group held 379 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $10.3K as of Q3 2019.
Rehmann Capital Advisory Group left its Horizon Therapeutics Public Limited Company Ordinary Shares share count unchanged in Q3 2019.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1040 holding.
Rehmann Capital Advisory Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2018 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $21.5K in Q1 2019.
264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.